TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05646381: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]

Sponsor: Novartis Pharmaceuticals · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 502 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,324,000

Rescue Site Savings

+$1,527,200

Unlock Full NCT05646381 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05646381 Rescue Dossier →